Early and sustained improvement in patient-reported outcomes and biomarker concentrations with tulisokibart induction in patients with moderately to severely active ulcerative colitis: A post-hoc analysis from ARTEMIS-UC

被引：0

作者：

Peyrin-Biroulet, L. ^{[1
]}

Yen, M. ^{[2
]}

Zhou, W. ^{[2
]}

Dong, B. ^{[2
]}

Danese, S. ^{[3
]}

Feagan, B. G. ^{[4
,5
]}

Sands, B. E. ^{[6
]}

机构：

[1] CHRU Nancy, INFINY Inst, Dept Gastroenterol, INSERM,NGERE, Nancy, France

[2] Merck & Co Inc, Merck Res Labs, Rahway, NJ USA

[3] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Gastroenterol & Gastrointestinal Endoscopy Unit, Milan, Italy

[4] Western Univ, Dept Med Epidemiol, London, ON, Canada

[5] Western Univ, Dept Biostat, London, ON, Canada

[6] Icahn Sch Med Mt Sinai, Dr Henry D Janowitz Div Gastroenterol, New York, NY USA

来源：

JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷

关键词：

D O I：

10.1093/ecco-jcc/jjae190.1259

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P1085

引用

页码：i1997 / i1998

页数：2

共 42 条